Physician, entrepreneur, and educator helping clinicians, health systems, and organizations navigate the new era of obesity pharmacotherapy — translating powerful medications into durable, real-world results.
Obesity medicine is entering its most consequential chapter. With price-accessible incretins reshaping the landscape, the question is no longer who can access these medications — it's who has the clinical expertise to deploy them effectively and the infrastructure to sustain results.
I'm a board-certified obesity medicine physician, the Cofounder and Chief Medical Officer of Accomplish Health, and faculty at the University of Oklahoma Health Sciences Center. At Accomplish, we built a fully virtual, insurance-covered obesity care model that combines medical expertise, FDA-approved treatments, personalized nutrition coaching, and connected technology. Our average outcomes exceed 20% total body weight loss at 12 months across four published cohorts.
My consulting practice focuses on real-world implementation: program design, clinical protocol development, provider education, and outcomes strategy for organizations navigating the transition from Era 1 to Era 2 of obesity pharmacotherapy.
Translating pharmacologic potential into clinical infrastructure, provider capability, and sustainable outcomes.
End-to-end architecture for health systems and practices launching or scaling obesity medicine — clinical protocols, staffing models, outcomes measurement, and multidisciplinary integration.
Practical frameworks for GLP-1 and dual/triple agonist prescribing: titration protocols, side-effect management, persistence strategies, and real-world optimization.
Grand rounds, CME programs, provider workshops, and clinical decision support tools for teams navigating the rapidly evolving incretin landscape.
Medical advisory for health tech, pharmaceutical, and digital health organizations — clinical strategy, product development, KOL engagement, and market positioning.
Data-driven review of existing programs with actionable recommendations to close the gap between trial-level efficacy and real-world results.
White papers, policy briefs, continuing education materials, and editorial content grounded in current evidence for clinical and executive audiences.
We are entering Era 2 of obesity pharmacotherapy — where broader access reshapes the landscape. But access alone does not guarantee outcomes. Clinical expertise will define them.
Read Essay →The KETO-CTA study finally put the lean mass hyper-responder hypothesis to a formal test. The results speak clearly — and instructively.
Read Essay →What employers and health plans need to understand about building real obesity treatment benefits — beyond the prescription.
Read Essay →Grand rounds, CME programs, conference keynotes, and provider workshops — helping clinicians navigate the rapidly evolving incretin landscape with confidence and rigor.
Whether you're building an obesity medicine program, looking for a clinical advisor, or interested in speaking and education — I'd like to hear from you.
I typically respond within 2 business days. For consulting engagements, we'll start with a 30-minute discovery call to understand your needs and determine fit.